Ratings TTY Biopharm Company Limited

Equities

4105

TW0004105002

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
76.6 ^TWD	+0.13%		+0.79%	-4.73%

Mar. 14	TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 08	TTY Biopharm Company Limited Announces Change of CFO and Financial Officer	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TTY BIOPHARM COMPANY LIMITED	-4.73%	584M	-
ELI LILLY AND COMPANY	+25.17%	661B	C+
NOVO NORDISK A/S	+26.74%	566B	B
JOHNSON & JOHNSON	-6.66%	352B	C+
MERCK & CO., INC.	+20.00%	332B	B-
ABBVIE INC.	+2.69%	283B	C+
ASTRAZENECA PLC	+13.43%	231B	B+
NOVARTIS AG	+4.71%	200B	B-
ROCHE HOLDING AG	-9.53%	195B	A+
AMGEN INC.	-5.22%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes